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Background: Glucocorticoids affect peripheral immune responses, including modulation of T-cell activation,
differentiation, and apoptosis. The quantity and quality of T-cell receptor (TCR)-triggered intracellular signals modulate
T-cell function. Thus, glucocorticoids may affect T cells by interfering with the TCR signaling cascade. The purpose of the
study was to search for glucocorticoid-modulated kinases downstream of the TCR.
Methods: Gene modulation in lymphoid cells either treated with glucocorticoids or from glucocorticoid-treated mice
was studied using a RNase protection assay, real-time PCR, and western blotting. The sensitivity of genetically modified
thymocytes to glucocorticoid-induced apoptosis was studied by performing hypotonic propidium iodide staining and
flow cytometry. The Student’s t-test was employed for statistical evaluation.
Results: We found that transcription of Itk, a non-receptor tyrosine kinase of the Tec family, was up-regulated in a mouse
T-cell hybridoma by the synthetic glucocorticoid dexamethasone. In contrast, dexamethasone down-regulated the
expression of Txk, a Tec kinase that functions redundantly with Itk, and Lck, the Src kinase immediately downstream of
the TCR. We investigated the expression of Itk, Txk, and Lck in thymocytes and mature lymphocytes following in vitro and
in vivo dexamethasone treatment at different time points and doses. Kinase expression was differentially modulated and
followed distinct kinetics. Itk was up-regulated in all cell types and conditions tested. Txk was strongly up-regulated in
mature lymphocytes but only weakly up-regulated or non-modulated in thymocytes in vitro or in vivo, respectively.
Conversely, Lck was down-regulated in thymocytes, but not modulated or up-regulated in mature lymphocytes in the
different experimental conditions. This complex behaviour correlates with the presence of both positive and negative
glucocorticoid responsive elements (GRE and nGRE, respectively) in the Itk, Txk and Lck genes. To investigate the function
associated with Itk up-regulation, dexamethasone-induced apoptosis of thymocytes from Itk-deficient mice was
evaluated. Our results demonstrated that Itk deficiency causes increased sensitivity to dexamethasone but not to
other pro-apoptotic stimuli.
Conclusions: Modulation of Itk, Txk, and Lck in thymocytes and mature lymphocytes is another mechanism by
which glucocorticoids modulate T-cell activation and differentiation. Itk up-regulation plays a protective role in
dexamethasone-treated thymocytes.
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Glucocorticoids are used to treat several autoimmune dis-
eases and prevent organ rejection following transplantation
due to their potent anti-inflammatory and immunosuppres-
sive activity. These compounds can also inhibit lymphocyte
proliferation and induce lymphocyte death [1-3]. However,
glucocorticoids have also been reported to potentiate the
immune response and modulate lymphocyte differentiation.
For example, when used in some experimental systems,
these compounds stimulate T-cell receptor (TCR)–medi-
ated T-cell proliferation and inhibit activation-induced cell
death [4]. At physiologic concentrations, glucocorticoids
shift immunity from a T helper (Th)1 to a Th2 response,
and promote production of T regulatory (Treg) cells [5-7].
This shift is also observed following long-term treatment
with glucocorticoids [8].
Recognition of the antigen-major histocompatibility com-
plex (MHC) by the TCR leads to a cascade of signaling
events initiated by activation of lymphocyte protein tyrosine
kinase (Lck), a Src-family kinase crucial in T-cell develop-
ment and activation [9]. Lck phosphorylates the cytoplas-
mic domain of CD3, leading to activation of ZAP-70, LAT,
and SLP-76, which in turn serve as a platform for recruiting
molecules, such as Tec kinases, into the signalosome [10].
Among Tec kinases, IL-2 inducible T cell kinase (Itk) is
expressed most highly and exerts the greatest effects on T-
cell function [11,12]. Txk tyrosine kinase (Txk) is a Tec kin-
ase that exhibits partial redundancy with Itk and is
expressed at lower levels than Itk [12]. Mice deficient in Itk
(Itk−/−) show altered T-cell development and impaired T-
cell effector function. Deletion of both Itk and Txk causes
marked defects in TCR responses, including proliferation,
cytokine production, and apoptosis in vitro, as well as a
dysfunctional immune response to Toxoplasma gondii in-
fection in vivo [13]. Molecular events immediately down-
stream of the TCR are intact in Txk−/−Itk−/− cells; however,
intermediate events such as inositol triphosphate produc-
tion, calcium mobilization, and mitogen-activated protein
kinase activation are impaired. These data establish Tec ki-
nases as critical regulators of TCR signaling required for
phospholipase C-γ activation [13].
Other data suggest that Itk and Txk play a divergent
role in T cell differentiation. Itk−/− mice are unable to
mount a Th2 response in models of allergic asthma [14],
as well as following infection with Leishmania major,
Nippostrongylus brasiliensis, and Schistosoma Mansoni,
which lead to Th1 cytokine production [15,16]. Surpris-
ingly Itk−/−Txk−/− mice mount Th2 responses, which
possibly suggests that these Tec kinases are involved in
Th1/Th2 polarization. Indeed, Txk over-expression has
been found to increase IFN-γ production. Moreover, in-
creased Txk expression has been observed in patients
with Behcet’s disease, a disorder associated with in-
creased inflammation and Th1 cytokine production [17].In this study, we demonstrate that the synthetic gluco-
corticoid dexamethasone modulates the expression of
Lck, Itk, and Txk in thymocytes and mature lymphocytes
in vitro and in vivo. In addition, we report that Itk up-
regulation in thymocytes has a functional role, as
demonstrated by the increased sensitivity of Itk−/− thy-
mocytes to dexamethasone-induced apoptosis. Thus, our
data suggest that glucocorticoids modulate T-cell func-
tion and the immune response by fine-tuning the ex-
pression of Lck and Tec kinases.
Methods
Animals
C3H and BALB/c mice were purchased from Jackson
Laboratory (Maine, USA). Itk−/− BALB/c mice were a
kind gift of dr. Locksley [15]. The animals were housed
in a controlled environment, provided with standard
rodent chow and water ad libitum and kept under spe-
cific pathogen-free conditions. Animal care was in com-
pliance with regulation in Italy (Decreto Ministeriale
116192), Europe (Official Journal of European Contract
Law 358/1 12/18/1986) and USA (Animal Welfare
Assurance No A5594-01, Department of Health and
Human Services, USA). The study was approved by the
Italian Ministero della Salute.
For in vivo experiments, female mice were injected
with 0.2 ml of saline solution or 5/25 mg/Kg dexametha-
sone in 0.2 ml saline solution and sacrificed 3 or 6 h
after treatment.
Cell isolation and treatment
Spontaneously dividing CD3+, CD4+, CD2+, CD44+ cells
of the OVA-specific hybridoma T-cell line 3DO [18] ob-
tained by recloning the original line in our laboratory
were used. Cells were maintained in logarithmic growth
at 37°C, 5% CO2 in RPMI 1640 medium supplemented
with fetal bovine serum (10%, FBS), 10 mM Hepes and
antibiotics and were treated with 10−7 M dexametasone
for 24 h.
Thymuses, spleens and cervical, brachial, axillary,
superficial inguinal and mesenteric lymph nodes were
isolated from 4- to 5-week old female C3H (in vitro/vivo
gene modulation experiments) or female BALB/c (apop-
tosis experiments) mice, teased in RPMI 1640 medium
and directly processed (in vivo experiment) or resus-
pended in RPMI 1640 supplemented with fetal bovine
serum (10%, FBS), 10 mM Hepes and antibiotics (in vitro
experiments). In treated groups, dexamethasone was
added for 1 and 3 h (RPA experiments and real-time
PCR, 10−7 M) or 18 h (apoptosis experiments, concen-
tration 2.5×10−8-10−7 M).
Total, CD4+ and CD8+ T lymphocytes were obtained
from spleen. Briefly, after red blood cell lysis, single cell
suspension was incubated either with CD4 plus CD8
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to get T lymphocytes or separately to obtain CD4+ and
CD8+ cells. Magnetic retained cells where then eluted from
LS columns according to the manufacturer’s instructions.
The purified cells were shown to be >98% CD3+, CD4+ or
CD8+ cells by flow cytometry.
Promoter analysis
Putative glucocorticoid responsive element (GRE) and
negative GRE (nGRE) sites within the murine regulatory
regions of Itk, Txk and Lck genes were analyzed by
MatInspector software algorithms (Genomatix). The
core similarity was set to 75%, while matrix similarity
was set to ≥0.85 (a perfect match to the matrix gets a
score of 1).
Differential display and cloning
RNA from untreated and dexamethasone-treated cells
was isolated using Trizol LS reagent (Ambion, Life
Technologies) according to the manufacturer’s instruc-
tions. Briefly, 750 μl TRIzol LS was added to 250 μl
medium containing 20–40 × 106 cells. After centrifuga-
tion with chloroform, RNA was precipitated by isopro-
panol and then washed with 75% ethanol.
DNA-free RNA (0.1 μg) was retrotranscribed (Molo-
ney murine leukemia virus reverse transcriptase from
Invitrogen, Life Technologies) with an anchored primer
(T11AC) and forty cycles of PCR were performed by
using T11AC and the OPA 5’-CGCGGAGGTG-3’ [19].
Three independent samples of untreated 3DO cells were
compared to three samples of 24 h dexamethasone-
treated 3DO cells, by SDS-polyacrylamide gel. The
radioactive band present in treated samples yet absent in
the untreated cells was extracted, cloned and sequenced.
PCR and RACE
RNA was purified and retrotranscribed as above speci-
fied but poly-T primer was used. To exclude any con-
tamination from cellular DNA, DNAse-treated RNA was
also used. Itk intron 5 was amplified by PCR using the
primers 5’-TGGGCTGTGTCTATTCCCTGCCATG-3’
and 5’-TAGAATTGTGGAGCTGAACAG-3’ and using
cDNA from RNA or DNA-free RNA. In order to further
exclude that Itk intron was amplified from DNA, PCR
was also performed with RNA that was not retrotran-
scribed. 5’ rapid amplification of cDNA ends (RACE)
was performed as previously described [20].
RNAse protection assay (RPA)
RNA was isolated as above specified and RPA was
performed as previously specified [21]. Probes for RNase
protection were constructed by RT-PCR using primers 5’-
GCTTGGTGCATATCCTTCATG-3’ and 5’-CGGTCAT
TTCAGGAACCTGAAG-3’ for Itk, 5’-AAAACATTCCCAGCGTCAGAGG-3’ and 5’-GCAGCGGCTTGCGCTTC
GAAGG-3’ for Txk and 5’-GAGCAGAGCGGTGAGTGG
TGG-3’ and 5’-TGCCGCTCGGCGTCCTTACGG-3’ for
Lck and inserted in the pCRII vector (Invitrogen, Life Tech-
nologies). pCRII-Itk, pCRII-Txk and pCRII-Lck RNA
probes were 301, 215, 273 bp long and protected a frag-
ment of 174 (encompassing exon 6 and 7), 88 (encompass-
ing exon 3 and 4), 146 bp (encompassing exon 4–6),
respectively. Plasmids were linearized with BamHI (New
England Biolabs). The probe giving a 250-bp fragment
(β-actin probe) protecting β-actin was purchased from
Ambion (Life Technologies), linearized with XbaI, and used
as internal control. All the probes were transcribed with T7
RNA polymerase (Ambion, Life Technologies) in the pres-
ence of 5 μCi [α-32P]UTP; β-actin was transcribed in the
presence of 0.5 μCi [α-32P]UTP. After washing out unin-
corporated nucleotides by quick spin columns (Fine Sepha-
dex G-50, GE Healthcare, Life Sciences), 5 × 105 cpm
probe (5 × 104 cpm β-actin) was hybridized to total cell
RNA (10 μg) and then incubated overnight at 60°C.
RNase digestion was performed by using an RNase A
(Roche)(40 μg/ml) and an RNase T1 (Ambion, Life Tech-
nologies)(1.5 U/μl) solution at 20°C for 5 min. The un-
digested products were treated with phenol-chloroform,
precipitated with ethanol, and loaded on a denaturing poly-
acrylamide sequencing gel. The gel was exposed to Biomax
MR Film Kodak (Sigma-Aldrich) with intensifying screens
at −70°C for 12 h to 2 days to obtain images of good
quality.
Quantitation of protected bands was obtained evaluating
cpm by Imager-Packard [22]. The ratio cpm of Itk, Txk or
Lck protected fragment/cpm of β-actin protected fragment
was calculated for each RNA and modulation of gene ex-
pression was equal to the ratio “value dexamethasone-
treated cells”/“value medium-treated cells” or “value cells
from dexamethasone-treated animals”/“value from saline
solution-treated animals” or “value from untreated ani-
mals”, as specified. In vitro and in vivo experiments were
performed three times. Cells of in vivo experiments were
pooled from 3–4 animals of the same experimental group.
Real time PCR
RNA was purified as above specified. Conversion of total
RNA (1 μg) to cDNA was performed with QuantiTect
Reverse Transcription protocol (Qiagen).
Real time PCR was done with a 7300 Real time PCR
system (Applied Biosystem) real time cycler using spe-
cific FAM/MGB dye-labeled TaqMan probes: Itk (Mm
00439862_m1), Txk (Mm 01213032_m1), Lck (Mm
00802897_m1). Gene expression was quantitated rela-
tively to the expression of endogenous control mouse
beta-actin (4352341e) VIC/MGB probe amplified in the
same tube of investigated genes. All probes were pur-
chased from Applied Biosystem. All experiments were
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to determine expression of the genes of interest, as pre-
viously described [23].
Western blotting
Cells were washed and lysed in SDS sample buffer for
30 min on ice. After centrifuging, the cleared lysates
were boiled and run in a 10% SDS-polyacrylamide gel.
The proteins were then transferred onto nitrocellulose
membranes, which were hybridized with rabbit anti-Itk
(Upstate, Merck-Millipore) antibody (Ab). Immunoreac-
tive protein bands were visualized using horseradish
peroxidase-conjugated goat anti-rabbit IgG (Pierce,
Thermo Scientific) followed by enhanced chemiolumi-
nescence (Merck-Millipore).
Western blot plates were scanned and band signal in-
tensities were determined using ImageJ software. Expres-
sion levels were normalized to β-tubulin (Sigma-Aldrich)
expression.
Apoptosis
Cells were treated with 10−7 M dexamethasone and
plastic-coated anti-CD3 Ab (0.5 μg/ml) (Pharmingen)
[24]. To evaluate heath shock-induced apoptosis, cells
were kept at 43°C for 10, 20 or 30 min. Before evaluating
the apoptosis levels by ipothonic propidium iodide stain-
ing [25], cells were cultured at 37°C, 5% CO2 for 18 h.
Flow cytometric analysis was conducted on a Beckman
Coulter EPICS XL-MCL running EXPO32 ADC analysis
software.
Statistical and mathematical analysis
Results were normally distributed and are the mean ±
SD. Student’s t-test was adopted for statistical evaluation
(*P < 0.05, **P < 0.01, ***P < 0.001). In apoptosis experi-
ments, apoptosis caused by the treatment (specific apop-
tosis percentage) was calculated as follows: 100×[%
apoptosis (treated cells)-% apoptosis (medium treated
cells)]/[100-% apoptosis (medium treated cells)].
Results
Dexamethasone up-regulates Itk expression but down-
regulates Txk and Lck in 3DO cells
We performed differential display to investigate Tec kin-
ase gene expression in 3DO T cells that were untreated
or treated for 24 h with the synthetic glucocorticoid
dexamethasone. A 275-bp cDNA segment was amplified
at much higher levels in dexamethasone-treated cells
compared to untreated cells. Upon sequencing and
alignment, this segment was identified as belonging to
the fifth intron of the Itk gene (Figure 1A). Because this
segment was not amplified in non-transcribed samples,
we concluded that the segment was derived from an
RNA sequence that was retrotranscribed into cDNA.However, NCBI databases do not contain EST sequences
and our attempts to clone a full-length cDNA containing
an open reading frame by rapid amplification of cDNA
ends (RACE) were unsuccessful. The only PCR product
that we obtained was a longer segment belonging to in-
tron 5 of Itk. The reason why an mRNA from an intron
was transcribed by reverse transcriptase and amplified
by differential display, PCR, and RACE remains unclear
and is under investigation. One possibility is that this re-
gion has regulatory functions or results from pre-mRNA
splicing, which is highly up-regulated by glucocorticoids.
We reasoned that if transcription of the intron is up-
regulated, Itk transcription should also be up-regulated.
Indeed, RNAse protection assay (RPA) confirmed our
hypothesis because Itk transcription was up-regulated
4-fold in 3DO cells (Figure 1B). Considering that Itk is a
kinase involved in TCR signaling, we investigated the ef-
fect of dexamethasone on the expression of other
kinases activated by TCR stimulation, focusing our at-
tention on Txk, the other relevant Tec kinase in T cells,
and on Lck. In 3DO cells, expression of Lck and Txk
was down-regulated by dexamethasone (Figure 1B),
thereby suggesting that Itk, Txk, and Lck may play dif-
ferent roles in glucocorticoid-treated lymphocytes.
Dexamethasone in vitro treatment up-regulates the
expression of Itk and Txk, but not Lck, in thymocytes and
peripheral T lymphocytes
Next, we examined the effect of dexamethasone on Itk,
Lck, and Txk gene expression in murine thymocytes,
splenocytes, and lymphocytes isolated from lymph nodes.
For this, we used RPA because of its high sensitivity and
accuracy in measuring mRNA levels [26,27]. For each
probe, the cpm of the fragment protected by the gene
under investigation was normalized to that protected by
β-actin. Gene modulation was then quantified as the ratio
of gene expression in treated versus untreated samples
(Figure 2). Our data show that Itk expression increased in
both thymocytes and peripheral T cells (Figure 3A), con-
firming the data obtained from dexamethasone-treated
3DO cells. Surprisingly, Txk expression also increased, al-
beit to a lower level than that of Itk (Figure 3B). Although
dexamethasone significantly decreased Lck expression in
thymocytes as previously demonstrated [28], little to no
effect was observed in mature T-cell populations
(Figure 3C).
Lck is expressed not only in T cells but also in NK cells,
B cells, and dendritic cells (DCs) [28]. The modulation ob-
served in spleen and lymph nodes may derive from modu-
lation of Lck in both T and other cells. Itk and Txk are
expressed almost exclusively in T and NK cells [12] but
modulation observed in splenocytes and lymph node T cells
may be due to indirect effects, such as interaction of T cells
with other glucocorticoid-treated cells present in the
Figure 1 Itk, Txk, and Lck gene expression is modulated by dexamethasone in the T cell hybridoma 3DO. (A) The DNA amplified and
isolated by the differential display technique (included in the box) is a 275-bp fragment belonging to intron 5 of the Itk gene in proximity to exon
6. In the original fragment, the first and last 10 bp were identical/complimentary to the OPA (the primer used in differential display) used in the
PCR reaction and overlapped only partially with the sequence of intron 5 (data not shown). (B) Itk, Txk, and Lck expression in 3DO cells is
modulated by 24-h treatment with dexamethasone (100 nM) as demonstrated by the RNAse protection assay. Fold modulation was calculated by
dividing the Itk/β-actin cpm ratio of DEX-treated cells by that of the respective untreated control. Values represent the mean (±SD) of three
independent experiments. ***P < 0.001, according to Student’s t-test comparing the levels of kinase mRNA in dexamethasone-treated cells to
those in medium-treated control cells.
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tion was induced by dexamethasone treatment of T cells,
we purified total, CD4+ and CD8+ T cells and evaluated the
effect of glucocorticoid treatment by real-time PCR. The
results confirmed that Itk and Txk expression in T cells
increases over time similar to expression in lymph node
cells from the same animals although the levels were lower
(Figure 3D-E). Lck expression was not modulated in either
T cells or lymph node cells (Figure 3F).
Itk, Txk, and Lck are also modulated by dexamethasone
treatment in vivo
We then proceeded to investigate whether dexametha-
sone affects the expression of these kinases in thymo-
cytes and splenocytes following in vivo treatment. Mice
were treated with either two doses of dexamethasone or
with saline solution and then sacrificed after 3 or 6 h.
The results show that Itk expression is significantly in-
creased upon administration of both low and high doses
of dexamethasone and that the increase is dose
dependent (Figure 4). Although Itk expression in the
thymus increased up to 6 h after administration, Itk ex-
pression in the spleen peaked at 3 h before returning to
control levels after 6 h. Interestingly, despite possible
differences between in vitro and in vivo treatments,
including cellular redistribution, cross-talk, and pharma-
cokinetics, treatment with dexamethasone for 3 h modu-
lated Itk expression similarly in vitro and in vivo. Of
note, a slight but significant increase in Itk expression
was also observed following saline treatment in both
thymocytes and splenocytes (Figure 4A). This increase
was most likely due to endogenous production of glu-
cocorticoids following manipulation stress, supporting
the idea that Itk modulation can occur with physio-
logic alteration of endogenous glucocorticoids. Theobserved up-regulation of Itk mRNA led to increased
Itk protein levels as demonstrated by western blot ana-
lysis (Figure 4C).
Evaluation of glucocorticoid-induced in vivo modulation
of the Txk gene revealed that, compared to saline-treated
mice, gene expression was increased slightly in peripheral
T cells after a 3 h treatment with the highest dexametha-
sone dose (Figure 5A, right panel), consistent with the
reduced responsiveness to dexamethasone treatment ob-
served in vitro. Both low and high dexamethasone doses
were effective in promoting Txk modulation after treat-
ment for 6 h. On the contrary, Txk expression did not
change significantly in thymocytes following in vivo dexa-
methasone treatment (Figure 5A, left panel). Compared to
saline-treated control animals, dexamethasone-treated
mice exhibited strong down-regulation of Lck expression
in the thymus (Figure 5B, left panel). This down-
regulation was dose-dependent and consistent with results
from the in vitro experiments. Comparison of saline-
treated and untreated mice revealed significantly de-
creased Lck expression in saline-treated mice (1.7 fold, P
< 0.01, data not shown). However, Lck was up-regulated
significantly in mature lymphocytes just 6 h after adminis-
tration of the highest dexamethasone dose (Figure 5B,
right panel). Taken together, Itk, Txk, and Lck were modu-
lated by dexamethasone treatment. Although these ki-
nases are activated upon T-cell activation and participate
in overlapping signaling pathways, dexamethasone modu-
lated each kinase differently (summarized in Table 1).
Thymocytes from Itk−/− mice were more sensitive to
dexamethasone treatment
To verify whether dexamethasone-induced Itk up-regu
lation plays a functional role, we treated Itk−/− thymocytes
with dexamethasone and evaluated apoptosis by flow
Figure 2 Itk gene expression is modulated in splenocytes.
RNAse protection assay was performed to evaluate the level of Itk
mRNA in splenocytes that were untreated (ctrl) or treated with
dexamethasone (DEX, 100 nM). The Itk probe protects a 174-bp
fragment and the β-actin probe protects a 250-bp fragment. A
representative experiment is shown in the top panel. After
autoradiographic exposure (shown in the figure), the radioactivity of
protected probes was evaluated using Instant Imager-Packard. The
Itk/β-actin cpm ratio is reported in the middle panel. Fold
modulation (bottom panel) was calculated by dividing the Itk/β-actin
cpm ratio of DEX-treated cells by that of the respective untreated
control. Values represent the mean (±SD) of three independent
experiments. Fold modulation, shown on a logarithmic scale base 2
(bottom panel), were statistically significant (**P < 0.01, according to
the Student’s t-test).
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Figure 6A and 6B (left panel) show that Itk−/− thymo-
cytes were more sensitive to dexamethasone-induced
apoptosis than wild type thymocytes. A significantly
higher percentage of apoptotic cells was observed even
at the lowest dexamethasone concentration. At thesame dexamethasone concentration (2.5 × 10−8 M), wild
type thymocytes exhibited similar levels of apoptosis to
that of untreated cells.
Interpretation of this data is complicated by the higher
level of spontaneous apoptosis observed in Itk−/− thymo-
cytes compared to wild type thymocytes. To compare the
levels of dexamethasone-induced apoptosis, we normalized
the data against the levels of spontaneous apoptosis
detected and then calculated dexamethasone-specific apop-
tosis (see Methods section for details). The differences in
specific apoptosis between Itk−/− and wild type thymocytes
were significant at each tested concentration (Figure 6B).
To evaluate whether this increased dexamethasone-
specific apoptosis in Itk−/− thymocytes was caused by a
greater susceptibility to apoptosis, we evaluated the
effect of other pro-apoptotic stimuli. Our data demon-
strate that Itk−/− thymocytes were not more sensitive
to apoptosis induced by anti-CD3 and heath shock
(Figure 6C and 6D). Therefore, increased apoptosis in
Itk−/− thymocytes suggests that Itk plays a protective
role in dexamethasone-induced apoptosis, which
works to counteract this biological phenomenon.
Discussion
In several cell types, including T cells, glucocorticoids
modulate the transcription of hundreds of genes whose
differential expression changes the fate and function of
cells, causing apoptosis, maturation, and differentiation
[1-3]. Here we demonstrate that dexamethasone modu-
lates Lck and Tec kinases rapidly in thymocytes and/or
mature lymphocytes. If we consider the pro-apoptotic
role of dexamethasone in thymocytes, we would expect
that genes with a pro-survival and activating function
are down-regulated. Surprisingly, while Lck expression
was found to be down-regulated, Tec kinase expression
was up-regulated by dexamethasone. The regulation of
Lck and Tec kinases was not coordinated even in mature
lymphocytes, further suggesting that the effects of gluco-
corticoids in T cells, and specifically T-cell activation,
are complex.
Our study clearly demonstrates for the first time that
dexamethasone up-regulates Itk expression in thymocytes.
In our previous study, we found that Itk was slightly up-
regulated in CD4+CD8+ double positive thymocytes treated
with dexamethasone for 3 h [23]. However, the up-
regulation was not validated using other techniques and the
increased expression appeared to be low (1.5-fold). The
higher level of up-regulation observed in this study (i.e.,
greater than 2-fold) may be the result of different
techniques and/or the presence of CD4+ and CD8+ single-
positive thymocytes. The up-regulation was very rapid be-
cause a greater than 2-fold increase was observed after 1 h
of dexamethasone treatment in vitro. Furthermore, these
data are quantitatively relevant because an approximately
Figure 3 Itk, Txk, and Lck mRNA levels were modulated by dexamethasone treatment of immature and mature lymphocytes in vitro.
Itk, Txk, and Lck mRNA levels were evaluated in thymocytes (gray triangle), splenocytes (black square), lymphocytes from lymph nodes (black
diamond), peripheral T lymphocytes (circle), CD4+ T cells (plus), and CD8+ T cells (asterisk) that were untreated (0 h) or treated with medium alone or
together with dexamethasone (DEX, 100 nM) for 1 or 3 h. Changes in mRNA expression were evaluated by RNAse protection assay and quantitated as
shown in Figure 2 (panels A-C) or validated by real-time PCR (panel D-F). Fold modulation of Itk (A, D), Txk (B, E), and Lck (C, F) expression is repre-
sented as the mean (±SD) of three independent experiments and is shown on a logarithmic scale (base 2). *P < 0.05, **P < 0.01, and ***P < 0.001, ac-
cording to Student’s t-test comparing the levels of kinase mRNA in dexamethasone-treated cells to those in the respective controls.
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in vivo, where the tested concentration was about 10-
fold higher than that tested in vitro. The up-regulation
of Itk in thymocytes following in vivo treatment confirms
the relevance of the in vitro data and demonstrates that it
is present despite the thymic microenvironment, including
TCR triggering and endogenous glucocorticoids. Itk up-
regulation protects thymocytes from dexamethasone-
induced apoptosis, as demonstrated by the specific
increased sensitivity of Itk−/− thymocytes to glucocorti-
coids along with their decreased/unchanged sensitivity
to other pro-apoptotic stimuli. In this context, the
increased level of Itk expression observed after in vivo
treatment with a high dose of dexamethasone may be
due, at least in part, to protection from dexamethasone-
induced apoptosis for those thymocytes with high levels
of Itk expression.A protective function for up-regulation of prosurvival
genes in cells undergoing apoptosis is well supported by
the literature. For example, a previous study from our
group demonstrated that 3-h dexamethasone treatment
of CD4+CD8+ double-positive thymocytes resulted in
transcriptional regulation of at least 10 genes with
known protective functions [23], including interleukin-7
receptor, which delivers anti-apoptotic and activating
signals to cells upon activation, and FKBP5 immunophi-
lin, which inhibits the interaction between glucocorti-
coids and their receptor. Interleukin-7 receptor was also
found to be up-regulated by glucocorticoids in mature T
cells [29]. Moreover, FKBP5 has been reported to be up-
regulated when endogenous glucocorticoid overproduc-
tion is stimulated [30].
Analysis of the presence of glucocorticoid responsive
elements (GRE) revealed a very well-conserved GRE
Figure 4 Itk expression is modulated by dexamethasone treatment in thymocytes and splenocytes in vivo. The level of Itk mRNA was
evaluated in thymocytes (left panels) and splenocytes (right panels) isolated from mice treated with 5 mg/kg (empty symbol) or 25 mg/kg (black
symbol) dexamethasone (DEX), or saline solution (S.S., asterisk). The animals were sacrificed 3 or 6 h after treatment. Changes in mRNA level were
evaluated by RNA protection assay and evaluated as shown in Figure 2. Fold modulation is represented as the mean (±SD) of three independent
experiments, with each experiment performed on cells pooled from three animals. The data are graphed on a logarithmic scale (base 2).
*P < 0.05, **P < 0.01, and ***P < 0.001, according to Student’s t-test comparing the levels of Itk mRNA in cells from treated animals to that in cells
from untreated animals (A) or from saline-treated animals (B). (C) Levels of Itk protein were evaluated in thymocytes from mice treated for 8 h
with 5 mg/kg dexamethasone (DEX) or saline solution (S.S.). The left panel shows one representative experiment (n = 4). After densitometric
analysis, the Itk/β-tubulin ratio (middle panel) and fold modulation (right panel) were calculated. ***P < 0.001, according to Student’s t-test
comparing the level of Itk protein in thymocytes from DEX-treated animals to that in thymocytes from untreated and saline-treated animals.
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Table S1 and Additional file 2: Figure S1) that may ac-
count for Itk up-regulation in thymocytes and peripheral
T cells. Surprisingly, we also found a well-conserved
negative GRE (nGRE) within the promoter region of Itk.
Differences in the extent of Itk up-regulation and its kin-
etics in cell lines, thymocytes, splenocytes, lymphocytes
from lymph nodes, and purified T lymphocytes may be
due to the balanced effects of GRE and nGRE, transcrip-
tion factors present in each cell type, basal level of ex-
pression of Itk in different cell types, and other signals
modulating the effects of glucocorticoids. Interestingly,Itk up-regulation is higher in lymphocytes from lymph
nodes than in splenocytes and T cells from splenocytes,
suggesting that the microenvironment from which T
cells are derived influences the effects of glucocorticoids.
Our data also reveal that Lck is down-regulated by
dexamethasone in thymocytes. This effect was observed
as early as 1 h after in vitro treatment and continued up
to 6 h in vivo. To the best of our knowledge, Lck down-
regulation has been reported by other studies but only
following long treatment times. In rat thymocytes, a 24-
h glucocorticoid treatment decreased Lck protein level
[31]. Moreover, in murine thymocytes (from a different
Figure 5 Txk and Lck gene expression is modulated by dexamethasone treatment of thymocytes and splenocytes in vivo. Levels of Txk
(A) and Lck (B) mRNA were evaluated in thymocytes (left panel) and splenocytes (right panel) from mice treated with 5 mg/kg (empty symbol) or
25 mg/kg (black symbol) dexamethasone, or saline solution. The animals were sacrificed 3 or 6 h after treatment. Changes in mRNA level were
evaluated by RNAse protection assay as shown in Figure 2. Fold modulation is represented as the mean (±SD) of three independent
experiments, with each experiment performed on cells pooled from three animals. The data are graphed on a logarithmic scale (base 2). *P < 0.05,
**P < 0.01, and ***P < 0.001, according to Student’s t-test comparing the levels of kinase mRNA in cells from treated animals to that in cells from
saline-treated animals.
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pression was observed after 12–24 h of glucocorticoid
treatment [28]. Inhibition of this kinase by treatment
with shRNA and the Src inhibitor dasatinib enhanced
thymocyte sensitivity to dexamethasone [28], suggesting
that Lck protects cells from glucocorticoid-induced
apoptosis. Low levels of Lck were found in T cells from
the spleen and lymph nodes of mice suffering from an
experimental graft-versus-host reaction (GVHR), and
Lck down-regulation was demonstrated to be dependent
on glucocorticoids [32]. In the same model, the level ofTable 1 Summary of kinase modulation following dexametha




Lymphocytes from peripheral organs Itk ↑↑↑
Txk ↑↑
Lck =
=,gene expression difference between treated and medium-treated samples/anima
↑ or ↓,The difference between treated and untreated samples is significant and has
↑↑ or ↓↓,The difference between treated and untreated samples is significant and h
↑↑↑ or ↓↓↓,The difference between treated and untreated samples is significant andLck in thymocytes remained unchanged with respect
to the control. Taken together, our results (short-term
treatment) are consistent with these reports (long-term
treatment), and suggest that glucocorticoid-mediated Lck
modulation is complex and time- and concentration-
dependent.
Surprisingly, we did not find sequences with a match to
nGRE matrixes greater than 0.85 (i.e., exhibiting a high
probability of binding GR and inhibiting transcription)
within the Lck promoter region. Instead, we found a se-
quence with a match to the GRE matrixes greater than 0.85sone treatment
Effect of dexamethasone treatment







ls is not significant;
a fold modulation (increase or decrease) lower than 1.6 or higher than −1.6.
as a fold modulation comprised between 1.6 and 2.2 or −1.6 and −2.2.
has a fold modulation higher than 2.2 or lower than −2.2.
Figure 6 Itk−/− thymocytes are more sensitive than wild type thymocytes to apoptosis induced by dexamethasone but not by TCR
activation or heat shock. (A) Itk−/− (KO) and wild type (WT) thymocytes were left untreated or treated with 10−7 M dexamethasone (DEX) for
18 h before staining with a hypotonic solution of propidium iodide followed by flow cytometric analysis for apoptotic cells. One representative
experiment performed on cells pooled from four mice is shown. The percentage of apoptotic cells within the gate is reported. (B) The
percentage of apoptotic cells following treatment with the specified concentration of DEX is represented as the mean (±SD) of four independent
experiments, performed on cells pooled from three to four mice. Because the level of spontaneous apoptosis was higher in KO than WT
thymocytes, apoptosis in DEX-treated cells was normalized using the respective level of spontaneous apoptosis and the DEX-specific apoptosis
was calculated as specified in Methods (right panel). (C) KO and WT thymocytes were treated with anti-CD3 antibody for 18 h and apoptosis was
evaluated as above. The percentage of apoptotic cells is represented as the mean (±SD) of four independent experiments, with each experiment
performed on cells pooled from three or four mice. Specific apoptosis is shown in the right panel. (D) KO and WT thymocytes were incubated at
43°C for the specified times and apoptosis was evaluated after a further 18 h as described above. The percentage of apoptotic cells is represented
as the mean (±SD) of four independent experiments, with each experiment performed on cells pooled from three or four mice. Specific apoptosis
is shown in the right panel. *P < 0.05, **P < 0.01, and ***P < 0.001, according to Student’s t-test comparing KO with WT apoptosis (left panel) or
DEX-specific apoptosis (right panel).
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Because data from this and other studies show that gluco-
corticoids down-regulate Lck expression in thymocytes, we
can conclude that this effect is due to heterodimerization of
activated GR to transcription factors and that the GRE
seems to be inactive in these cells. On the contrary, the up-regulation found in splenocytes after treatment for 6 h
in vivo may be due to the GRE.
Investigation of the Txk promoter revealed three and two
very well-conserved GRE and nGRE motifs, respectively
(Additional file 1: Table S1 and Additional file 2: Figure S1).
These data suggest that Txk expression is strictly controlled
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dependent Txk modulation between thymocytes and
T lymphocytes from peripheral organs may reflect the bal-
ance between GRE- and nGRE-mediated regulation.
Glucocorticoids affect peripheral immune responses by
inhibiting T cell immunity at several stages of the activation
cascade. Because the thymic epithelium produces steroids, it
is reasonable to hypothesize that endogenous glucocorticoids
also play a role in controlling T-cell development [33,34].
Brewer and colleagues showed that apoptosis induced by
TCR triggering is mediated by glucocorticoids in murine thy-
mocytes. Reports have also described glucocorticoid-
mediated transcriptional regulation of TCR complex proteins
[21,35,36], as well as modulation of TCR function and signal-
ing transduction [37-40]. In particular, glucocorticoid treat-
ment has been shown to modulate kinase activity in activated
T cells [41]. As both peripheral responsiveness and thymic
differentiation appear to be regulated by the quantity and
quality of intracellular signals triggered by TCR activation,
the interference of glucocorticoids on the expression of ki-
nases downstream of the TCR may contribute to the effect of
endogenous and pharmacological glucocorticoids on Tcells.
Our study demonstrates for the first time that both Tec
kinases are up-regulated in splenocytes and lymphocytes.
However, Itk up-regulation was more rapid and quantita-
tively relevant considering that the basal levels of Itk expres-
sion are higher than that of Txk in mature lymphocytes [12].
Several findings suggest that Itk activity favors differentiation
towards the Th2 phenotype [14-16,42]. The various effects
of glucocorticoids on T cell differentiation in the different
experimental models and human diseases depend on several
factors; however, data suggest that glucocorticoids favor Th2
and Treg differentiation of CD4+ T cells [5,7,8]. In this
context, it is likely that dexamethasone-induced Itk up-
regulation is at least partly responsible for the Th2-polarizing
effects of glucocorticoids. Moreover, Itk seems to favor
Th17-induced T regulatory cell (iTreg) polarization [43]
whereas glucocorticoids enhance the Th17/Th1 imbalance
in patients with systemic lupus erythematosus [44].
Conclusions
Modulation of TCR signaling by glucocorticoids is known to
involve several mechanisms, including regulation of TCR
complex subunit expression and kinase activity. In this study,
we show that Itk, Txk, and Lck expression is modulated by
dexamethasone in thymocytes and mature lymphocytes,
demonstrating another mechanism by which glucocorticoids
modulate T-cell activation. Furthermore, we reveal that
dexamethasone-driven Itk up-regulation plays a protective
role in glucocorticoid-induced thymocyte apoptosis. Dexa-
methasone was also found to induce differential expression
of Itk and Txk in mature lymphocytes, possibly favoring T-
cell polarization. Future studies are required to address the
actual in vivo relevance of such a mechanism.Additional files
Additional file 1: Table S1. Putative glucocorticoid responsive element
(GRE) and negative GRE (nGRE) sites within the murine Itk, Txk and Lck
genes.
Additional file 2: Figures S1. The putative Glucocorticoid Responsive
Element (GRE) and negative GRE (nGRE) sites in murine Itk, Txk and Lck
genes.
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